Skip to main content
. 2022 Feb 15;37(4):687–699. doi: 10.1002/jbmr.4503

Fig. 4.

Fig. 4

Anti‐sclerostin antibody‐treatment leads to increased serum phosphate levels and decreased serum FGF23 levels. Serum creatinine (A), phosphate (B), FGF23 (C), and PTH (D) levels in mice treated with anti‐sclerostin antibody or vehicle, exposed to a warfarin‐containing or control diet. FGF23 = fibroblast growth factor 23, PTH = parathyroid hormone.